Q-Tor Drug Interactions

HMG-CoA reductase inhibitors: Risk of myopathy.
Antacid: Decreased plasma concentrations of Atorvastatin approximately 35%.
Antipyrine: Because Atorvastatin does not affect the pharmacokinetics of Antipyrine.
Colestipol: Plasma concentrations of Atorvastatin decreased approximately 25%.
Cholestyramine: No data is available.
Cimetidine: Atorvastatin plasma concentrations and LDL-C reduction were not altered.
Digoxin: Increased steady-state plasma digoxin concentrations by approximately 20%.
Erythromycin: Plasma concentrations of Atorvastatin increased approximately 40%.
Oral contraceptives: Increased AUC values of norethindrone and ethinylestradiol approximately 30% and 20%, respectively.
Warfarin: Atorvastatin had no clinical significant effect on prothrombin time when administered to patients receiving combined Atorvastatin and warfarin therapy for two weeks. Nevertheless, patients receiving Atorvastatin should be closely monitored when Atorvastatin is combined with warfarin therapy.
Other Concomitant Therapy: In clinical studies, Atorvastatin was used concomitantly with antihypertensive agents and oestrogen replacement therapy without evidence of clinically significant adverse interactions. Interaction studies with specific agents have not been conducted.